BDX 📈 Becton Dickinson - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US0758871091

BDX: Medical Devices, Laboratory Equipment, Diagnostic Products, Syringes, Needles

Becton, Dickinson and Company is a global leader in the medical technology industry, providing a wide range of innovative products and solutions to healthcare institutions, physicians, researchers, and the general public worldwide.

The company operates through three main segments: BD Medical, BD Life Sciences, and BD Interventional. BD Medical focuses on developing and manufacturing medical supplies, devices, and equipment for various healthcare settings. This includes products such as IV catheters, syringes, needles, and medication delivery systems, as well as solutions for medication safety, infusion therapy, and supply management.

In addition to medical supplies, BD Medical also offers a range of products for vascular access, anesthesia, and enteral nutrition, as well as systems for medication compounding, automated dispensing, and inventory management. This segment is dedicated to improving patient care and safety, while also enhancing the efficiency and effectiveness of healthcare providers.

BD Life Sciences, on the other hand, is focused on advancing the discovery and diagnosis of diseases. This segment offers a broad portfolio of products and solutions for specimen collection, blood and tuberculosis culturing, molecular testing, and microbiology laboratory automation. BD Life Sciences also provides a range of reagents, antibodies, and kits for gene expression analysis, as well as diagnostic and monitoring tools for clinical oncology, immunology, and transplantation.

The BD Interventional segment is dedicated to developing and manufacturing innovative products for surgical and interventional procedures. This includes hernia and soft tissue repair products, biological and bioresorbable grafts, biosurgery products, and surgical infection prevention solutions. The segment also offers peripheral intervention products, urology and critical care products, and other surgical solutions designed to improve patient outcomes and reduce healthcare costs.

With a rich history dating back to 1897, Becton, Dickinson and Company is headquartered in Franklin Lakes, New Jersey, and is committed to advancing the world of health through innovative solutions and partnerships. To learn more about the company and its products, visit https://www.bd.com.

Additional Sources for BDX Stock

BDX Stock Overview

Market Cap in USD 65,078m
Sector Healthcare
Industry Medical Instruments & Supplies
GiC Industry Health Care Equipment & Supplies
TER 0.00%
IPO / Inception 1987-01-01

BDX Stock Ratings

Growth 5y -2.16%
Fundamental 27.2%
Dividend 47.4%
Rel. Performance Sector -1.77
Analysts 4.33/5
Fair Price Momentum 194.40 USD
Fair Price DCF 288.39 USD

BDX Dividends

Dividend Yield 12m 1.72%
Yield on Cost 5y 1.60%
Annual Growth 5y 4.00%
Payout Consistency 80.77%

BDX Growth Ratios

Growth Correlation 3m -43.9%
Growth Correlation 12m -15.7%
Growth Correlation 5y 27.7%
CAGR 5y -1.36%
CAGR/Mean DD 5y -0.12
Sharpe Ratio 12m -0.37
Alpha -22.14
Beta 0.47
Volatility 16.86%
Current Volume 2493.7k
Average Volume 20d 2006.9k
What is the price of BDX stocks?
As of December 04, 2024, the stock is trading at USD 221.26 with a total of 2,493,745 shares traded.
Over the past week, the price has changed by -1.33%, over one month by -5.58%, over three months by -8.26% and over the past year by -5.35%.
Is Becton Dickinson a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, Becton Dickinson is currently (December 2024) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 27.23 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of BDX as of December 2024 is 194.40. This means that BDX is currently overvalued and has a potential downside of -12.14%.
Is BDX a buy, sell or hold?
Becton Dickinson has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy BDX.
  • Strong Buy: 9
  • Buy: 6
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0
What are the forecast for BDX stock price target?
According to ValueRays Forecast Model, BDX Becton Dickinson will be worth about 210.2 in December 2025. The stock is currently trading at 221.26. This means that the stock has a potential downside of -5.01%.
Issuer Forecast Upside
Wallstreet Target Price 280.9 26.9%
Analysts Target Price 301.2 36.1%
ValueRay Target Price 210.2 -5%